Arca
Skip to content
Tools
Tools

Glutamate [NMDA] receptor

Complex group in Homo sapiens that 20 drugs act on.

  • Drugs that act on it: 20
  • Approved: 7
  • In phases 1 to 3: 12
  • Sponsors: 12
  • Genes: 7

Who is on it, and how far along

Every drug ChEMBL records acting on GRIN1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 16
  • Protein or peptide 2
  • Other 2

Approved7

  • Ketamine
  • Esketamine
  • Amantadine
  • Memantine
  • Acamprosate
  • Orphenadrine
  • Felbamate

Phase 34

  • AV-101
  • Neramexane
  • Ralfinamide
  • Rapastinel

Phase 27

  • Apimostinel
  • Delucemine
  • GW468816
  • Indantadol
  • Lanicemine
  • Neboglamine
  • Perzinfotel

Phase 11

  • AZD8108

Preclinical or unknown1

  • CNS-5161

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Naurex, Inc, an affiliate of Allergan plc210%
  • Ache Laboratorios Farmaceuticos S.A.15%
  • Newron Pharmaceuticals SPA15%

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 12 of 20 act as: Glutamate [NMDA] receptor antagonist; the rest name their own mechanism.
KetamineApprovedPH HealthSmall moleculeNegative allosteric modulatorGlutamate [NMDA] receptor negative allosteric modulator408
EsketamineApprovedJohnson & JohnsonSmall moleculeNegative allosteric modulatorGlutamate [NMDA] receptor negative allosteric modulator126
AmantadineApprovedEndo InternationalSmall moleculeAntagonist39
MemantineApprovedAbbVieSmall moleculeNegative allosteric modulatorGlutamate [NMDA] receptor negative allosteric modulator36
AcamprosateApprovedAbbVieSmall moleculeAntagonist5
OrphenadrineApprovedAche Laboratorios Farmaceuticos S.A.Small moleculeAntagonist2
FelbamateBoxed warningApprovedViatrisSmall moleculeAntagonist0
AV-101Phase 3Aerovate TherapeuticsSmall moleculeAntagonist0
NeramexanePhase 3Merz GroupSmall moleculeAntagonist0
RalfinamidePhase 3Newron Pharmaceuticals SPASmall moleculeAntagonist0
RapastinelPhase 3Naurex, Inc, an affiliate of Allergan plcProtein or peptidePartial agonistGlutamate [NMDA] receptor partial agonist0
ApimostinelPhase 2Naurex, Inc, an affiliate of Allergan plcProtein or peptidePartial agonistGlutamate [NMDA] receptor partial agonist1
DeluceminePhase 2—Small moleculeAntagonist0
GW468816Phase 2—Small moleculeAntagonist0
IndantadolPhase 2Vernalis (R&D) LtdOtherAntagonist0
LaniceminePhase 2AstraZeneca PharmaceuticalsSmall moleculeBlockerGlutamate [NMDA] receptor blocker0
NeboglaminePhase 2—Small moleculePositive allosteric modulatorGlutamate [NMDA] receptor positive allosteric modulator0
PerzinfotelPhase 2—Small moleculeAntagonist0
AZD8108Phase 1—OtherAntagonist0
CNS-5161Preclinical or unknown—Small moleculeBlockerGlutamate [NMDA] receptor blocker0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 30 in all, from ClinicalTrials.gov.
Esketamine Plus Sirolimus for Adults With Depression Who Have Not Responded to EsketamineEsketamine, KetaminePhase 2Not yet recruitingRodolfo Furlan DamianoNov 19, 2026
Low vs. High Dose Oral Midazolam-Ketamine for Pediatric IV CannulationKetaminePhase 4Active, not recruitingIbrahim Elabd Hassan MohamedNov 18, 2026
Ketamine for Treatment of Alzheimers Disease Related DepressionKetaminePhase 2Not yet recruitingVanderbilt University Medical CenterNov 17, 2026
Intranasal Esketamine-dexmedetomidine Combination in Patients With Postherpetic NeuralgiaEsketamine, KetaminePhase 4Not yet recruitingPeking University First HospitalNov 13, 2026
Prolonged Multimodal Analgesia for Postsurgical PainEsketamine, KetamineNot applicableNot yet recruitingBeijing Tiantan HospitalNov 13, 2026
Longitudinal Assessment of Biomarkers Among Patients With MDDEsketamine, Ketamine—RecruitingMassachusetts General HospitalNov 12, 2026
Exploring Ketamine's Effects on Depression and Anxiety in Adults With Low VisionKetaminePhase 2Not yet recruitingStanford UniversityNov 12, 2026
Enhancing the Effect of Stellate Ganglion Block in the Treatment of PTSD: Bupivacaine vs Bupivacaine + KetamineKetaminePhase 2Not yet recruitingThe Royal's Institute of Mental Health ResearchNov 9, 2026
Intranasal Dexmedetomidine-esketamine Combination and Postoperative Cognitive Recovery in Older PatientsEsketaminePhase 4Not yet recruitingPeking University First HospitalNov 4, 2026
Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean SectionEsketamineNot applicableNot yet recruitingAnhui Provincial HospitalNov 4, 2026
Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer PatientsAmantadinePhase 2Not yet recruitingAl-Azhar UniversityOct 22, 2026
Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of StayEsketaminePhase 2Not yet recruitingUniversity of Sao PauloOct 22, 2026
Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic SurgeryEsketaminePhase 4Not yet recruitingTianjin Medical University Cancer Institute and HospitalOct 22, 2026
Memantine Targeting Neurovascular Dysfunction After Mild and Moderate Traumatic Brain Injury (MEND)Amantadine, MemantinePhase 2Not yet recruitingNova Scotia Health AuthorityOct 9, 2026
Synaptic Mechanisms of Continuous Theta Burst Stimulation in DepressionAmantadine, MemantineEarly phase 1RecruitingMclean HospitalMay 1, 2026
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver DiseaseAcamprosateNot applicableNot yet recruitingYale UniversityApr 28, 2026
Escalating Doses of Memantine in Down Syndrome (MEDS-123)Amantadine, MemantinePhase 1Not yet recruitingUniversity Hospitals Cleveland Medical CenterApr 15, 2026
SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain MetastasesMemantinePhase 2Not yet recruitingNational Taiwan University HospitalApr 1, 2026
Neuroprotection of Memantine and RosuvastatinAmantadine, MemantinePhase 2 / Phase 3Not yet recruitingTanta UniversityMar 31, 2026
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the BrainAmantadine, MemantinePhase 2RecruitingThe University of Texas Health Science Center at San AntonioMar 13, 2026
Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain SyndromeAmantadineNot applicableRecruitingCairo UniversityFeb 19, 2026
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type DementiaAmantadine, MemantinePhase 3RecruitingBigespas LTDNov 26, 2025
Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)MemantinePhase 2RecruitingCase Comprehensive Cancer CenterNov 25, 2025
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)AcamprosatePhase 1RecruitingNational Institute of Neurological Disorders and Stroke (NINDS)Oct 3, 2025
Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism PainOrphenadrinePhase 4RecruitingUniversity of BaghdadAug 7, 2025
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) TrialAcamprosatePhase 2RecruitingSamer GawriehJul 11, 2025
Apimostinel + Automated Neurocognitive Training for DepressionApimostinelPhase 2RecruitingRebecca PriceMay 6, 2024
Combining a Smartphone App With Medications to Manage Heavy DrinkingAcamprosateNot applicableRecruitingVA Office of Research and DevelopmentMar 12, 2024
Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use DisorderAcamprosatePhase 4RecruitingNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Feb 21, 2024
Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With CirrhosisOrphenadrinePhase 3RecruitingSherief Abd-ElsalamApr 22, 2015

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094124, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.